Measures of Cortical Microstructure Are Linked to Amyloid Pathology in Alzheimer’s Disease

Markers of downstream events are a key component of clinical trials of disease-modifying therapies for Alzheimer’s disease. Morphological metrics like cortical thickness are established measures of atrophy but are not sensitive enough to detect Aβ-related changes that occur before overt atrophy become visible. We aimed to investigate to what extent diffusion-MRI can provide sensitive markers of cortical microstructural changes and to test their associations with multiple aspects of the Alzheimer’s disease pathological cascade, including both Aβ and tau accumulation, astrocytic activation and cognitive deficits. We applied the mean apparent diffusion propagator model to diffusion-MRI data from 492 cognitively unimpaired elderly and patients with mild cognitive impairment from the Swedish BioFINDER-2 cohort. Participants were stratified in Aβ-negative/tau-negative, Aβ-positive/tau-negative, and Aβ-positive/tau-positive based on Aβ- and tau-PET uptake. Cortical regional values of diffusion-MRI metrics and cortical thickness were compared across groups. Associations between regional values of diffusion-MRI metrics and both Aβ- and tau-PET uptake were also investigated along with the association with plasma level of glial fibrillary acidic protein (GFAP), a marker of astrocytes activation (available in 292 participants). Mean squared displacement revealed widespread microstructural differences already between Aβ-negative/tau-negative and Aβ-positive/tau-negative participants with a spatial distribution that closely resembled the pattern of Aβ accumulation. In contrast, differences in cortical thickness were clearly more limited. Mean squared displacement was also correlated with both Aβ- and tau-PET uptake even independently from one another and from cortical thickness. Further, the same metric exhibited significantly stronger correlations with PET uptake than cortical thickness (p < 0.05). Mean squared displacement was also positively correlated with GFAP with a pattern that resemble Aβ accumulation, and GFAP partially mediated the association between Aβ accumulation and mean squared displacement. Further, impairments in executive functions were significantly more associated with mean squared displacement values extracted from a meta-ROI encompassing regions accumulating Aβ early in the disease process, than with cortical thickness (p < 0.05). Similarly, impairments in memory functions were significantly more associated with mean squared displacement values extracted from a temporal meta-ROI, than with cortical thickness (p < 0.05). Metrics of cortical microstructural alteration derived from diffusion-MRI are highly sensitive to multiple aspects of the Alzheimer’s disease pathological cascade. Of particular interest is the link with both Aβ-PET and GFAP suggesting diffusion-MRI might reflects microstructural changes related to the astrocytic response to Aβ aggregation. Therefore, metrics of cortical diffusion might be important outcome measures in anti-Aβ treatments clinical trials for detecting drug-induced changes in cortical microstructure.